James A. Brink, M.D., FACR, chair of the American College of Radiology (ACR) Board of Chancellors, met with the House Committee on Science, Space and Technology Subcommittee on Energy to urge more research on low-dose medical radiation effects to inform future safety practices. He also told the Committee that medical imaging and radiation oncology save lives.

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.

November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy of culprit lesion-only percutaneous coronary intervention (PCI) reduces the composite of 30-day mortality and/or severe renal failure in patients with multivessel disease and cardiogenic shock complicating acute myocardial infarction.

October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the incidence of no-reflow phenomenon after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) patients with attenuated plaque ≥5mm based upon intravascular imaging. It also examined its long-term effects.

Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery. Results of the economic analysis, which is the first-of-its-kind report on intermediate-risk patients, were presented as a late-breaking clinical trial at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim three-year study results from the ABSORB III pivotal clinical trial continue to show increased rates of major adverse cardiac events and stent thrombosis in patients receiving the Absorb GT1 bioresorbable vascular scaffold (BVS) compared to Abbott’s approved metallic Xience drug-eluting stent (DES). The information was delivered in an update to the March 18, 2017 letter to providers.

October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left main coronary artery disease (LMCAD) receiving percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) found significant and similar QoL improvement at three years, although a greater benefit was observed with PCI at one month.

The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published new guidelines for the treatment of patients with ventricular arrhythmias and the prevention of sudden cardiac death.

October 30, 2017 — Researchers have discovered a previously unrecognized healing capacity of the heart. In a mouse model, they were able to reverse severe heart failure by silencing the activity of Hippo, a signaling pathway that can prevent the regeneration of heart muscle. The study appears in the journal Nature.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now